234 related articles for article (PubMed ID: 16596777)
21. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.
Shim JY; Welsh WJ; Howlett AC
Biopolymers; 2003; 71(2):169-89. PubMed ID: 12767117
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.
Talwar R; Potluri VK
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):536-44. PubMed ID: 21631407
[TBL] [Abstract][Full Text] [Related]
23. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.
Pandey P; Roy KK; Liu H; Ma G; Pettaway S; Alsharif WF; Gadepalli RS; Rimoldi JM; McCurdy CR; Cutler SJ; Doerksen RJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30322136
[TBL] [Abstract][Full Text] [Related]
24. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
25. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
Asproni B; Murineddu G; Corona P; Pinna GA
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
[TBL] [Abstract][Full Text] [Related]
26. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
[TBL] [Abstract][Full Text] [Related]
27. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes.
Huffman JW; Padgett LW
Curr Med Chem; 2005; 12(12):1395-411. PubMed ID: 15974991
[TBL] [Abstract][Full Text] [Related]
28. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells.
Jiang S; Fu Y; Williams J; Wood J; Pandarinathan L; Avraham S; Makriyannis A; Avraham S; Avraham HK
PLoS One; 2007 Jul; 2(7):e641. PubMed ID: 17653268
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.
Tuccinardi T; Ferrarini PL; Manera C; Ortore G; Saccomanni G; Martinelli A
J Med Chem; 2006 Feb; 49(3):984-94. PubMed ID: 16451064
[TBL] [Abstract][Full Text] [Related]
30. Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Foloppe N; Benwell K; Brooks TD; Kennett G; Knight AR; Misra A; Monck NJ
Bioorg Med Chem Lett; 2009 Aug; 19(15):4183-90. PubMed ID: 19520572
[TBL] [Abstract][Full Text] [Related]
31. Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors.
Reggio PH
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):143-60. PubMed ID: 12052032
[TBL] [Abstract][Full Text] [Related]
32. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
33. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators.
Yuan J; Jiang C; Wang J; Chen CJ; Hao Y; Zhao G; Feng Z; Xie XQ
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056767
[TBL] [Abstract][Full Text] [Related]
34. Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.
Westphal MV; Sarott RC; Zirwes EA; Osterwald A; Guba W; Ullmer C; Grether U; Carreira EM
Chemistry; 2020 Jan; 26(6):1380-1387. PubMed ID: 31961047
[TBL] [Abstract][Full Text] [Related]
35. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
37. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
Gado F; Meini S; Bertini S; Digiacomo M; Macchia M; Manera C
Future Med Chem; 2019 Aug; 11(15):2019-2037. PubMed ID: 31517528
[TBL] [Abstract][Full Text] [Related]
38. Adamantyl cannabinoids: a novel class of cannabinergic ligands.
Lu D; Meng Z; Thakur GA; Fan P; Steed J; Tartal CL; Hurst DP; Reggio PH; Deschamps JR; Parrish DA; George C; Järbe TU; Lamb RJ; Makriyannis A
J Med Chem; 2005 Jul; 48(14):4576-85. PubMed ID: 15999995
[TBL] [Abstract][Full Text] [Related]
39. The therapeutic potential of novel cannabinoid receptors.
Kreitzer FR; Stella N
Pharmacol Ther; 2009 May; 122(2):83-96. PubMed ID: 19248809
[TBL] [Abstract][Full Text] [Related]
40. Oxa-adamantyl cannabinoids.
Ho TC; Tius MA; Nikas SP; Tran NK; Tong F; Zhou H; Zvonok N; Makriyannis A
Bioorg Med Chem Lett; 2021 Apr; 38():127882. PubMed ID: 33636308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
